Epidemiology, risk factors and management of cardiovascular diseases in IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 1, 2015, Pages 26-35

  Singh, Siddharth ^a   Kullo, Iftikhar J ^a   Pardi, Darrell S ^a   Loftus, Edward V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE;

ANEMIA; ARTERIAL STIFFNESS; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATORY BOWEL DISEASE; ISCHEMIC HEART DISEASE; LEUKOCYTOSIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; THERAPY EFFECT; THROMBOCYTE DYSFUNCTION; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; GENETICS; INFLAMMATORY BOWEL DISEASES; METABOLISM; VASCULAR ENDOTHELIUM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATORY BOWEL DISEASES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 84925010358     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.202     Document Type: Review

References (97)

1. Nguyen, G. C. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146, 835-848 (2014).
2. Yuhara, H. et al. Meta-Analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 37, 953-962 (2013).
3. Grainge, M. J., West, J., & Card, T. R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657-663 (2010).
4. Piazza, G., & Goldhaber, S. Z. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 121, 2146-2150 (2010).
5. Sorensen, H. T., Horvath-Puho, E., Pedersen, L., Baron, J. A., & Prandoni, P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370, 1773-1779 (2007).
6. Becattini, C., Vedovati, M. C., Ageno, W., Dentali, F., & Agnelli, G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-Analysis. J. Thromb. Haemost. 8, 891-897 (2010).
7. Bernstein, C. N., Wajda, A., & Blanchard, J. F. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin. Gastroenterol. Hepatol. 6, 41-45 (2008).
8. Kristensen, S. L. et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death-A Danish nationwide cohort study. PLoS ONE 8, e56944 (2013).
9. Rungoe, C. et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 62, 689-694 (2013).
10. Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J., & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-Analysis of observational studies. Ann. Rheum. Dis. 71, 1524-1529 (2012).
11. Maradit-Kremers, H., Nicola, P. J., Crowson, C. S., Ballman, K. V., & Gabriel, S. E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 52, 722-732 (2005).
12. Symmons, D. P., & Gabriel, S. E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol. 7, 399-408 (2011).
13. Ahlehoff, O. et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J. Intern. Med. 270, 147-157 (2011).
14. Kristensen, S. L. et al. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish nationwide cohort study. Circ. Heart Fail. 7, 717-722 (2014).
15. Yarur, A. J. et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am. J. Gastroenterol. 106, 741-747 (2011).
16. Singh, S., Singh, H., Loftus, E. V. Jr, & Pardi, D. S. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta analysis. Clin. Gastroenterol. Hepatol. 12, 382-393 (2014).
17. Dorn, S. D., & Sandler, R. S. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-Analysis. Am. J. Gastroenterol. 102, 662-667 (2007).
18. Singh, S., & Loftus, E. V. Jr. Cardiovascular risk in inflammatory bowel disease: it's a heartache! Gastroenterology 145, 1484-1486 (2013).
19. Ha, C., Magowan, S., Accortt, N. A., Chen, J., & Stone, C. D. Risk of arterial thrombotic events in inflammatory bowel disease. Am. J. Gastroenterol. 104, 1445-1451 (2009).
20. Shaw, L. J., Bugiardini, R., & Merz, C. N. Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol. 54, 1561-1575 (2009).
21. Claassen, M., Sybrandy, K C., Appelman, Y. E., & Asselbergs, F. W. Gender gap in acute coronary heart disease: myth or reality?. World J. Cardiol. 4, 36-47 (2012).
22. Cook, N. R., Buring, J. E., & Ridker, P. M. The effect of including C reactive protein in cardiovascular risk prediction models for women. Ann. Intern. Med. 145, 21-29 (2006).
23. Andersohn, F., Waring, M., & Garbe, E. Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm. Bowel Dis. 16, 1387-1392 (2010).
24. Lusis, A. J. Atherosclerosis. Nature 407, 233-241 (2000).
25. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
26. Hansson, G. K., Robertson, A. K., & Soderberg Naucler, C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 1, 297-329 (2006).
27. Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M., & Sitzer, M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-Analysis. Circulation 115, 459-467 (2007).
28. Papa, A. et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 22, 839-846 (2005).
29. Theocharidou, E., Gossios, T. D., Giouleme, O., Athyros, V. G., & Karagiannis, A. Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology 65, 284-293 (2014).
30. Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-Analysis. J. Am. Coll. Cardiol. 55, 1318-1327 (2010).
31. Zanoli, L. et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J. Hypertens. 30, 1775-1781 (2012).
32. Zanoli, L. et al. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs. Atherosclerosis 234, 346-351 (2014).
33. Gutierrez, E. et al. Endothelial dysfunction over the course of coronary artery disease. Eur. Heart J. 34, 3175-3181 (2013).
34. Anderson, T. J. et al. Microvascular function predicts cardiovascular events in primary prevention: long-Term results from the Firefighters and Their Endothelium (FATE) study. Circulation 123, 163-169 (2011).
35. Pepine, C. J. et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J. Am. Coll. Cardiol. 55, 2825-2832 (2010).
36. Kerekes, G. et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat. Rev. Rheumatol. 8, 224-234 (2012).
37. Roifman, I. et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 7, 175-182 (2009).
38. Principi, M. et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J. Crohns Colitis 7, 427-433 (2013).
39. Aloi, M. et al. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J. Pediatr. 161, 589-594 (2012).
40. Danesh, J. et al. C reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004).
41. Averill, M. M., Kerkhoff, C., & Bornfeldt, K. E. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler. Thromb. Vasc. Biol. 32, 223-229 (2012).
42. Croce, K. et al. Myeloid-related protein 8/14 is critical for the biological response to vascular injury. Circulation 120, 427-436 (2009).
43. Ionita, M. G. et al. High myeloid-related protein: 8/14 levels are related to an increased risk of cardiovascular events after carotid endarterectomy. Stroke 41, 2010-2015 (2010).
44. Jensen, L. J. et al. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J. Interv. Cardiol. 23, 123-129 (2010).
45. Oussalah, A., Gueant, J. L., & Peyrin-Biroulet, L. Meta-Analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 34, 1173-1184 (2011).
46. Drzewoski, J., Gasiorowska, A., Malecka Panas, E., Bald, E., & Czupryniak, L. Plasma total homocysteine in the active stage of ulcerative colitis. J. Gastroenterol. Hepatol. 21, 739-743 (2006).
47. Hankey, G. J., & Eikelboom, J. W. Homocysteine and vascular disease. Lancet 354, 407-413 (1999).
48. Boushey, C. J., Beresford, S. A., Omenn, G. S., & Motulsky, A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049-1057 (1995).
49. Koutroubakis, I. E. et al. Anti-cardiolipin and anti b2 glycoprotein I antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 43, 2507-2512 (1998).
50. Koutroubakis, I. E. et al. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?. Eur. J. Gastroenterol. Hepatol. 13, 1415-1419 (2001).
51. Adler, J., Rangwalla, S. C., Dwamena, B. A., & Higgins, P. D. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-Analysis. Am. J. Gastroenterol. 106, 699-712 (2011).
52. Galluzzo, S. et al. Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. Hum. Immunol. 72, 636-640 (2011).
53. El Mokhtari, N. E. et al. Role of NOD2/CARD15 in coronary heart disease. BMC Genet. 8, 76 (2007).
54. Gawaz, M., Langer, H., & May, A. E. Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378-3384 (2005).
55. Danese, S., Motte Cd Cde, L., & Fiocchi, C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 99, 938-945 (2004).
56. Webberley, M. J., Hart, M. T., & Melikian, V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 34, 247-251 (1993).
57. Collins, C. E., Cahill, M. R., Newland, A. C., & Rampton, D. S. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 106, 840-845 (1994).
58. Danese, S. et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124, 1249-1264 (2003).
59. Osterman, M. T. et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin. Gastroenterol. Hepatol. 9, 875-880 (2011).
60. Inamdar, S., Altafi, S., & Sultan, K. Increased risk of coronary artery disease among patients with inflammatory bowel disease. Gastroenterology 142, S792 (2012).
61. Haapamaki, J., Roine, R. P., Turunen, U., Farkkila, M. A., & Arkkila, P. E. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J. Crohns Colitis 5, 41-47 (2011).
62. Tan, V. P., Chung, A., Yan, B. P., & Gibson, P. R. Venous and arterial disease in inflammatory bowel disease. J. Gastroenterol. Hepatol. 28, 1095-1113 (2013).
63. Robertson, J., Peters, M. J., McInnes, I. B., & Sattar, N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat. Rev. Rheumatol. 9, 513-523 (2013).
64. Ripolles Piquer, B. et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism 55, 980-988 (2006).
65. Sappati Biyyani, R. S., Putka, B. S., & Mullen, K. D. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J. Clin. Lipidol. 4, 478-482 (2010).
66. Romanato, G. et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment. Pharmacol. Ther. 29, 298-307 (2009).
67. Koutroubakis, I. E. et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21, 283-288 (2009).
68. Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998).
69. Sappati Biyyani, R. S., Fahmy, N. M., Baum, E., Nelson, K. M., & King, J. F. Inflammatory bowel disease and coronary artery disease. Indian J. Gastroenterol. 28, 28-30 (2009).
70. Wei, L., MacDonald, T. M., & Walker, B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 141, 764-770 (2004).
71. Carty, E., MacEy, M., & Rampton, D. S. Inhibition of platelet activation by 5 aminosalicylic acid in inflammatory bowel disease. Aliment. Pharmacol. Ther. 14, 1169-1179 (2000).
72. Prufer, J. et al. Harmful effects of the azathioprine metabolite 6 mercaptopurine in vascular cells: induction of mineralization. PLoS ONE 9, e101709 (2014).
73. Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-Alpha, in patients with moderate to severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133-3140 (2003).
74. Dixon, W. G. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-Tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905-2912 (2007).
75. Szekanecz, Z., Kerekes, G., & Soltesz, P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol. 5, 677-684 (2009).
76. van Sijl, A. M. et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203934.
77. Tam, L. S. et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis-A randomized trial. J. Rheumatol. 39, 2267-2275 (2012).
78. Chan, S. S. et al. Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Aliment. Pharmacol. Ther. 34, 649-655 (2011).
79. Ananthakrishnan, A. N. et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann. Intern. Med. 156, 350-359 (2012).
80. Takeuchi, K. et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4, 196-202 (2006).
81. Vinod, J. et al. The effect of antiplatelet therapy in patients with inflammatory bowel disease. J. Clin. Gastroenterol. 46, 527-529 (2012).
82. Patel, S. H., Rachchh, M. A., & Jadav, P. D. Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. Indian J. Pharmacol. 44, 744-748 (2012).
83. Carty, E., Rampton, D. S., Schneider, H., Rutgeerts, P., & Wright, J. P. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. Aliment. Pharmacol. Ther. 15, 1323-1329 (2001).
84. Tytgat, G. N., Van Nueten, L., Van De Velde, I., Joslyn, A., & Hanauer, S. B. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment. Pharmacol. Ther. 16, 87-99 (2002).
85. Ky, B., & Rader, D. J. The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. Clinical Cardiol. 28, 67-70 (2005).
86. Lee, J. Y. et al. Simvastatin inhibits NF ?B signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int. Immunopharmacol. 7, 241-248 (2007).
87. Naito, Y. et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int. J. Mol. Med. 17, 997-1004 (2006).
88. Sasaki, M. et al. The 3 hydroxy 3-methylglutaryl CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J. Pharmacol. Exp. Ther. 305, 78-85 (2003).
89. Abe, Y. et al. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig. Dis. Sci. 57, 335-344 (2012).
90. Grip, O., & Janciauskiene, S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS ONE 4, e5263 (2009).
91. Crockett, S. D. et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm. Bowel Dis. 18, 1048-1056 (2012).
92. Cho, S. J. et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-Associated colon cancer in mice. Int. J. Cancer 123, 951-957 (2008).
93. Samadder, N. J. et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 117, 1640-1648 (2011).
94. Jaszewski, R. et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. Gastroenterology 98, 1543-1548 (1990).
95. Wengrower, D. et al. Prevention of fibrosis in experimental colitis by captopril: the role of TGF-b1. Inflamm. Bowel Dis. 10, 536-545 (2004).
96. Crowson, C. S. et al. Rheumatoid arthritis and cardiovascular disease. Am. Heart J. 166, 622-628 (2013).
97. Aggarwal, A., Atreja, A., Kapadia, S., Lopez, R., & Achkar, J. P. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm. Bowel Dis. 20, 1593-1601 (2014).